Literature DB >> 23245668

Botulinum neurotoxin serotype D is poorly effective in humans: an in vivo electrophysiological study.

Roberto Eleopra1, Cesare Montecucco, Grazia Devigili, Christian Lettieri, Sara Rinaldo, Lorenzo Verriello, Marco Pirazzini, Paola Caccin, Ornella Rossetto.   

Abstract

OBJECTIVE: Botulinum neurotoxins act on nerve endings and block neurotransmitter release. Their potency is due to their enzymatic activity and high affinity binding to neurons. Botulinum toxin type A is used in the treatment of human diseases characterized by hyperactivity of peripheral cholinergic nerve terminals, but some patients are or become resistant to it. This can be overcome by using other botulinum toxins, and studies have been performed with different toxin serotypes. Botulinum neurotoxin type D has never been tested in humans in vivo, and, therefore, we investigated the action of this toxin in mouse and human muscles.
METHODS: Botulinum toxin type D potency was determined on mouse hemidiaphragm and on rat neuronal cultures. From these experiments, doses to be injected in human volunteers were decided. The compound muscle action potential of toxin-injected Extensor Digitorum Brevis muscle was measured at different times points after injection in human volunteers.
RESULTS: Botulinum toxin type D is poorly effective in inducing human skeletal muscle paralysis.
CONCLUSIONS: Botulinum toxin type D is very potent in mice and almost ineffective in humans in vivo. SIGNIFICANCE: The results shed new light on the mechanism of toxin type D binding to the neuronal surface receptors.
Copyright © 2012 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23245668     DOI: 10.1016/j.clinph.2012.11.004

Source DB:  PubMed          Journal:  Clin Neurophysiol        ISSN: 1388-2457            Impact factor:   3.708


  22 in total

1.  Activity of botulinum neurotoxin type D (strain 1873) in human neurons.

Authors:  Sabine Pellett; William H Tepp; Jacob M Scherf; Christina L Pier; Eric A Johnson
Journal:  Toxicon       Date:  2015-04-30       Impact factor: 3.033

Review 2.  Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology.

Authors:  Marco Pirazzini; Ornella Rossetto; Roberto Eleopra; Cesare Montecucco
Journal:  Pharmacol Rev       Date:  2017-04       Impact factor: 25.468

3.  Substrate cleavage and duration of action of botulinum neurotoxin type FA ("H, HA").

Authors:  Sabine Pellett; William H Tepp; Guangyun Lin; Eric A Johnson
Journal:  Toxicon       Date:  2017-12-19       Impact factor: 3.033

4.  Selective cleavage of SNAREs in sensory neurons unveils protein complexes mediating peptide exocytosis triggered by different stimuli.

Authors:  Jianghui Meng; J Oliver Dolly; Jiafu Wang
Journal:  Mol Neurobiol       Date:  2014-03-08       Impact factor: 5.590

5.  Botulinum toxin type D blocks autonomic cholinergic synapses in humans: discussion of a potential therapeutic use.

Authors:  Dirk Dressler; Katja Kollewe; Tilmann H C Kruger; Niklas Gade; Stefan Sikorra; Hans Bigalke
Journal:  J Neural Transm (Vienna)       Date:  2019-06-15       Impact factor: 3.575

6.  Botulinum neurotoxins A, B, C, E, and F preferentially enter cultured human motor neurons compared to other cultured human neuronal populations.

Authors:  Sabine Pellett; William H Tepp; Eric A Johnson
Journal:  FEBS Lett       Date:  2019-07-04       Impact factor: 4.124

7.  Preparation of Cerebellum Granule Neurons from Mouse or Rat Pups and Evaluation of Clostridial Neurotoxin Activity and Their Inhibitors by Western Blot and Immunohistochemistry.

Authors:  Domenico Azarnia Tehran; Marco Pirazzini
Journal:  Bio Protoc       Date:  2018-07-05

8.  The Use of Botulinum Toxin for Treatment of the Dystonias.

Authors:  Alfredo Berardelli; Antonella Conte
Journal:  Handb Exp Pharmacol       Date:  2021

Review 9.  Toxicology and pharmacology of botulinum and tetanus neurotoxins: an update.

Authors:  Marco Pirazzini; Cesare Montecucco; Ornella Rossetto
Journal:  Arch Toxicol       Date:  2022-03-25       Impact factor: 6.168

10.  Structural analysis of Clostridium botulinum neurotoxin type D as a platform for the development of targeted secretion inhibitors.

Authors:  Geoffrey Masuyer; Jonathan R Davies; Kevin Moore; John A Chaddock; K Ravi Acharya
Journal:  Sci Rep       Date:  2015-09-01       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.